Articles by Wafik El-Deiry, MD, PhD, FACP
Dr. El-Deiry expands on reducing ALDH1 expression in HT29 cells, and the benefits of targeting ERK1/2 and STAT3 activation.
Dr. Wafik El-Deiry of Brown University discusses his study on regorafenib with TAS-102 for colorectal cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.